Bithionol inhibits ovarian cancer cell growth In Vitro - studies on mechanism(s) of action

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ayyagari, Vijayalakshmi N ^a   Brard, Laurent ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autotaxin; Bithionol; Ovarian cancer cell lines; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BITHIONOL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; NF-KAPPA B; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORIC DIESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84893198454     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-61     Document Type: Article

References (62)

1. American Cancer Society Cancer facts and figures 2013. Atlanta, Ga. American Cancer Society 2013, 18. American Cancer Society.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
3. Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep 2006, 8(6):448-454. 10.1007/s11912-006-0074-9, 17040623.
4. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3(7):502-516. 10.1038/nrc1123, 12835670.
5. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 34:1-6.
6. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial EOC: three-year results. J Natl Cancer Inst 2000, 92:699-708. 10.1093/jnci/92.9.699, 10793106.
7. Kikuchi Y. The mechanism of cisplatin-resistance in ovarian cancer. Hum Cell 2001, 14(2):115-133.
8. Leitao MM, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 2003, 91:123-129. 10.1016/S0090-8258(03)00464-5, 14529671.
9. Lamberth E, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer 2004, 14:772-778. 10.1111/j.1048-891X.2004.014507.x, 15361183.
10. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm 2007, 340:117-126.
11. Bacq Y, Besnier JM, Duong TH, Pavie G, Metman EH, Choutet P. Successful treatment of acute fascioliasis with bithionol. Hepatology 1991, 14:1066-1069. 10.1002/hep.1840140620, 1959855.
12. Braddock D. Autotaxin and lipid signaling pathways as anticancer targets. Curr Opin Investig Drugs 2010, 11:629-637.
13. Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther 2008, 7(10):3352-3362. 10.1158/1535-7163.MCT-08-0463, 18852138.
14. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 2010, 79(9):1272-1280. 10.1016/j.bcp.2009.12.021, 2834878, 20067776.
15. Kasibhatla S, Amarante-Mendes GP, et al. Staining of suspension cells with Hoechst 33258 to detect apoptosis. CSH Protoc 2006, 2006(3). doi:10.1101/pdb.prot4492.
16. Razzell WE, Khorana HG. Studies on polynucleotides. III. Enzymatic degradation; substrate specificity and properties of snake venom phosphodiesterase. J Biol Chem 1959, 234:2105-2113.
17. Lowry OH, Rosebrough NJ, Farr A, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
18. Yokogawa M, Yoshimura H, Okura T, Sano M, Tsuji M, Iwasaki M, Hirose H. Chemotherapy of paragonimiasis with bithionol. II. Clinical observations on the treatment with bithionol. Jap J Parasitol 1961, 10:317.
19. Arts HJ, Van Der Zee AG, De Jong S, De Vries EG. Options for modulation of drug resistance in ovarian cancer. Int J Gynecol Cancer 2000, 10(S1):47-52. 10.1046/j.1525-1438.2000.99511.x, 11240733.
20. Deigner HP, Kinscherf R. Modulating apoptosis: current applications and prospects for future drug development. Curr Med Chem 1999, 6:399-414.
21. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000, 256:42-49. 10.1006/excr.2000.4838, 10739650.
22. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays 2000, 22:1007-1017. 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4, 11056477.
23. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995, 182(2):367-377. 10.1084/jem.182.2.367, 2192111, 7629499.
24. Englert RP, Shacter E. Distinct modes of cell death induced by different reactive oxygen species: amino acyl chloramines mediate hypochlorous acid-induced apoptosis. J Biol Chem 2002, 277:20518-20526. 10.1074/jbc.M200212200, 11925431.
25. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000, 6:379-392. 10.2174/1381612003400948, 10788588.
26. McDonald ER, El-Deiry WS. Cell cycle control as a basis for cancer drug development. Int J Oncol 2000, 16:871-886.
27. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512. 10.1101/gad.13.12.1501, 10385618.
28. Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007, 13(11):3370-3379. 10.1158/1078-0432.CCR-07-0164, 2505183, 17545545.
29. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature (London) 1996, 381:643-644. 10.1038/381643a0, 8649505.
30. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994, 79:551-555. 10.1016/0092-8674(94)90540-1, 7954821.
31. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163. 10.1101/gad.9.10.1149, 7758941.
32. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell CL, Swindell E, Fox MP, Wei N. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995, 6:387-400. 10.1091/mbc.6.4.387, 301199, 7626805.
33. Conklin KA. Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004, 3:294-300. 10.1177/1534735404270335, 15523100.
34. Meshkini A, Yazdanparast R. Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol 2012, 64(4):357-365. 10.1016/j.etp.2010.09.010, 21074392.
35. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J of Cancer 2007, 120(1):175-180.
36. Watson AS, Mortensen M, Simon AK. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle 2011, 10(11):1719-1725. 10.4161/cc.10.11.15673, 3142456, 21512311.
37. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000, 87:179-183. 10.1161/01.RES.87.3.179, 10926866.
38. Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 2013, 3(120):1-10. 3555505, 23373009.
39. Page CH, Lin J, Jin Y, Castle VP, Nunez G, Huang M, Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000, 20:407-416.
40. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI-3 K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005, 97:26-34. 10.1016/j.ygyno.2004.11.051, 15790433.
41. Rokudai S, Fujita N, Kitahara O, Nakamura Y, Tsuruo T. Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol 2002, 22(24):8695-8708. 10.1128/MCB.22.24.8695-8708.2002, 139879, 12446787.
42. Asselin E, Mills GB, Tsang BK. XIA P regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001, 61(5):1862-1868.
43. Bharti AC, Aggarwal BB. Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemo sensitization. Ann N Y Acad Sci 2002, 973:392-395. 10.1111/j.1749-6632.2002.tb04671.x, 12485899.
44. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999, 5:412-417. 10.1038/7410, 10202930.
45. Cusack JC, Liu R, Baldwin AS. NF-κB and chemoresistance: potentiation of cancer drugs via inhibition of NF-κB. Drug Resist Updat 1999, 2:271-273. 10.1054/drup.1999.0094, 11504498.
46. Toledano MB, Leonard WJ. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 1991, 88(10):4328-4332. 10.1073/pnas.88.10.4328, 51652, 1903539.
47. Liu J, Yoshida Y, Yamashita U. DNA-binding activity of NF-kappaB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase. Mol Immunol 2008, 45(15):3984-3989. 10.1016/j.molimm.2008.06.012, 18657320.
48. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 2002, 64(5-6):963-970.
49. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 2002, 5(3-4):131-146.
50. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007, 13(23):7191-7198. 10.1158/1078-0432.CCR-07-0362, 18056200.
51. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995, 11:1217-1228.
52. Herod JO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996, 56:2178-2184.
53. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML. Autotaxin (ATX), a potent tumor mitogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19:241-247. 10.1038/sj.onc.1203263, 10645002.
54. Nam SW, Clair T, Kim YS, et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001, 61:6938-6944.
55. Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal 2010, 22(6):926-935. 10.1016/j.cellsig.2010.01.017, 20100569.
56. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995, 1:1223-1232.
57. Xu Y, Xiao YJ, Zhu K, Baudhuin LM, Lu J, Hong G, Kim KS, Cristina KL, Song L, Elson P, Markman M, Belinson J. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 2003, 3:23-32. 10.2174/1568008033340414, 12570723.
58. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, Xu Y. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 2007, 26:2894-2901. 10.1038/sj.onc.1210093, 17130843.
59. Brindley DN, Pilquil C. Lipid phosphate phosphatases and signaling. J Lipid Res 2009, 50:S225-S230. 2674702, 19066402.
60. Ye X, Ishii I, Kingsbury MA, Chun J. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 2002, 1585:108-113. 10.1016/S1388-1981(02)00330-X, 12531543.
61. Tigyi G, Parrill AL. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 2003, 42:498-526. 10.1016/S0163-7827(03)00035-3, 14559069.
62. Awada R, Rondeau P, Grès S, Saulnier-Blache JS, Lefebvre d'Hellencourt C, Bourdon E. Autotaxin protects microglial cells against oxidative stress. Free Radic Biol Med 2012, 52(2):516-526. 10.1016/j.freeradbiomed.2011.11.014, 22155714.